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Abstract
Background: Burst stimulation is a novel form of neurostimulation for the treatment of chronic pain which
has demonstrated promise in small uncontrolled studies, but has not yet gained approval for use in the U.S.
We report the study methods for an ongoing multicenter, randomized, controlled, cross-over study designed
to gain United States Food and Drug Administration (FDA) approval for burst stimulation.
Methods: Participants who are candidates for a currently approved neurostimulation device were enrolled
and screened. Participants who fail a tonic trial evaluation, have significant depressive symptoms, or
evidence lack of compliance with study procedures by failing to complete 7 days of a Pain Diary are
excluded. Participants receiving a permanent implant are randomized to receive: (1) 12 weeks of tonic
followed by 12 weeks of burst stimulation or (2) 12 weeks of burst stimulation followed by 12 weeks of
tonic stimulation. Assessments occur at 6, 12, 18, and 24 weeks. After 24 weeks, participants choose their
preferred therapy and are assessed every 6 months for up to 2 years. All patients had the device leads
inserted at the site of a successful tonic stimulation trial. Assessments include: a Pain Diary using a Visual
Analog Scale (VAS) for overall, trunk, and limb pain, the Beck Depression Inventory, the Pain Catastrophizing
Scale, the Oswestry Disability Index, paresthesia, satisfaction, and therapy preference. Reported adverse
events are collected throughout the study. The primary endpoint is the noninferiority of burst stimulation
compared to tonic measured by the within-subject difference in the mean overall VAS score at the end of
each 12-week stimulation period.
Discussion: This trial represents the largest controlled trial of burst stimulation to date, and is expected to
yield important information regarding the safety and efficacy of burst stimulation.
Trial registration: ClinicalTrials.gov, NCT02011893. Registered on 10 December 2013.
Keywords: Neuromodulation, Spinal cord Stimulation, Randomized, Prospective, Comparative efficacy, Burst
stimulation, Tonic stimulation
* Correspondence: kslavin@uic.edu
1Department of Neurosurgery, University of Illinois College of Medicine, 912
South Wood St, Chicago, IL, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Slavin et al. Trials  (2016) 17:569 
DOI 10.1186/s13063-016-1706-5
Background
Spinal cord stimulation (SCS) is an established therapy to
treat chronic, intractable pain of the trunk and limbs [1].
Traditional SCS produces tonic waveforms in which
pulses are delivered at a consistent frequency, pulse width,
and amplitude. New technological developments using
alternate waveforms to stimulate the dorsal column and/
or aim at new stimulation targets show promising results
[2]. Burst stimulation, in particular, is a waveform that
delivers groups of pulses at a high frequency and at
amplitudes much lower than tonic stimulation; these
groups of pulses are separated by a pulse-free period
called an interburst interval during which passive re-
polarization occurs prior to the next burst. This pat-
tern was chosen because this burst waveform mimics
naturally occurring neuronal firing in the central
nervous system [3].
The use of the burst waveform in SCS for the treat-
ment of chronic pain was first reported in 2010 [4].
Since that time, reports from multiple, relatively small,
clinical studies have shown that burst stimulation pro-
vides effective pain control, which, in some patients,
may surpass the pain relief provided by tonic stimulation
[5–8]. In these studies, the additional pain reduction
during burst stimulation was relatively only marginally
smaller compared with tonic stimulation results, but
burst stimulation was preferred by a majority of patients
in spite of the similar pain-reducing profile. Some
evidence indicates that burst stimulation may provide a
salvage therapy option for patients who fail to achieve
adequate pain control with tonic stimulation or for those
in whom the initial efficacy of tonic stimulation is lost
over time [7, 8].
A common element in all previous clinical studies is
the marked reduction or total absence of paresthesia
during burst stimulation. Tonic stimulation is predicated
on the use of paresthesiae to “cover” painful areas, and
little evidence has been reported for efficacious therapy
when tonic stimulation is delivered at subperception
levels. Alternatively, burst stimulation appears to pro-
duce paresthesia in only a subset of patients, approxi-
mately 17–25% [4, 7, 8], and anecdotal reports indicate
that paresthesiae during burst stimulation may be quali-
tatively different from those experienced during tonic
stimulation. Perceptual difference in the patient experi-
ence may exert an indirect influence on patient-reported
outcomes.
To date, the mechanisms and clinical effects of the
burst waveform have been mainly studied in small co-
horts of patients in Europe and Australia over a short
duration (e.g., 2–4 weeks). Larger, longer-term, con-
trolled clinical studies of the burst waveform are lacking.
Burst stimulation has not yet been approved for use in
the U.S. Here, we report the study methods for an
ongoing multicenter, cross-over, randomized controlled
study designed to gain United States Food and Drug




Under an Investigational Device Exemption (IDE), the
objective of the study (protocol C-12-07 ver 8.28.14) is
to demonstrate safety and efficacy for burst stimulation.
As such, the study examines burst stimulation compared
to the traditional SCS stimulation mode (tonic stimula-
tion). The primary objective of the study is to establish
noninferiority of pain intensity after 3 months of burst
compared to 3 months of tonic stimulation. Previous
studies [5–8] indicated that burst stimulation was pre-
ferred by most subjects even when the magnitude of
pain relief was similar. Therefore, the primary objective
of noninferiority of pain intensity will establish the ther-
apy as comparable for pain relief to traditional tonic
stimulation, and secondary objectives (listed below) will
examine the superiority of pain relief and other out-
comes that may elucidate the patient experience of burst
stimulation.
Secondary objectives are:
 To demonstrate differences between tonic and burst
stimulation in responder rate
 To demonstrate significant differences in the
presence of paresthesia during tonic stimulation and
burst stimulation
 To demonstrate that pain relief using burst
stimulation is superior to pain relief using tonic
stimulation
 To demonstrate differences between tonic and burst
stimulation adverse events
 To demonstrate differences between tonic and burst
stimulation for quality of life
 To demonstrate differences between tonic and burst
stimulation for worst pain
 To demonstrate differences between tonic and burst
stimulation for function
Additional analyses will examine these objectives after
12 months of therapy.
Trial design
The study consists of two distinct phases: (1) a 24-week
controlled (cross-over) phase during which participants
are randomly assigned to one of two treatment se-
quences of tonic and burst stimulation, each for
12 weeks and (2) an open-label phase during which
participants may use either waveform (see Figs. 1 and
2). With guidance from the FDA, the study employs
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enrichment strategies aimed at decreasing variability
and assessing the efficacy of burst compared to an
approved SCS waveform. As such, participants are
limited to those who achieve adequate pain relief
during a traditional tonic stimulation trial evaluation;
all participants use both waveforms in a within-subject
cross-over design.
At up to 20 centers in the U.S., Institutional Review
Board (IRB) approval is obtained (refer to its “Declara-
tions” page), and eligible enrolled participants undergo
additional screening and participate in a standard SCS
trial evaluation using tonic stimulation. Those with a
successful SCS trial evaluation are implanted with the
Prodigy™ neurostimulation system (St. Jude Medical,
Fig. 1 Study design. Schematic of the study design and follow-up schedule
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Plano, TX, USA) that can deliver both burst and tonic
waveforms. Lead position for the permanent system is
determined by placement for optimum paresthesia cover-
age during the tonic stimulation trial evaluation. After a
2–3 week surgical recovery period, participants with the
permanent system are randomized to receive one of the
two treatment sequences over the subsequent 24 weeks.
During the control phase, participants use one wave-
form for 12 weeks then cross over to the other waveform
for the remaining 12 weeks. Participants are randomly
assigned (1:1) at each study site using computer-generated
assignment to receive 12 weeks of tonic stimulation
followed by 12 weeks of burst stimulation, or 12 weeks of
burst stimulation followed by 12 weeks of tonic stimula-
tion. Participants in both groups complete assessments at
6, 12, 18, and 24 weeks after randomization.
To enhance participant compliance with the study
protocol, a washout period was not employed when par-
ticipants crossed over. This decision was based on previ-
ous reports suggesting that 25–80% of patients may fail to
comply with the study protocol when asked to undergo
periods without stimulation [9, 10]. Assessments occur at
a minimum of 6 weeks after changing stimulation
modes, which is adequate time to ensure that any
after-effects of the previous therapy will not influence
the assessment of the current therapy [11, 12].
During the open-label phase of the study, participants
attend study visits for assessment every 6 months for up
to 2 years post randomization. Perceptible differences in
paresthesia between the two waveforms are likely, thus
neither patients nor investigators are blinded to treat-
ment sequence.
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure
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Any changes to the protocol will be reported to the
IRB for each site and to the FDA. The protocol, and this
reported version of the protocol conform to the Stand-
ard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines; a copy of the SPIRIT Check-
list accompanies this report as part of the supplemental
materials (see Additional file 1).
Participants
Participants with chronic neuropathic pain of the trunk
and/or limbs are invited to consider study participation.
After signing an informed consent, enrolled participants
are evaluated for compliance with the inclusion/exclu-
sion criteria (see Table 1). Participants who fail to com-
ply with the Pain Diary assessment (see “Assessments”
section) are excluded from the study. Participants who
evidence moderate-to-severe depression and/or suicidal
ideation, measured by the Beck Depression Inventory II
(BDI-II), do not meet the criteria and are excluded from
the study. This was derived, with guidance from the
FDA, to select participants who were free from serious
affective comorbidities requiring behavioral/pharmaco-
logical interventions in addition to pain therapy. Partici-
pants were prohibited from increasing the dosage of
pain medications, with the exception of acetaminophen,
during the first 24 weeks of the study. Participants were
not required to stop or decrease pain medications at any
time during the study.
Interventions
The SCS trial evaluation period, per usual care
(approximately 3 to 10 days), is performed with epidural
leads placed percutaneously under local anesthesia and
connected to an external pulse generator that delivers
tonic stimulation (St. Jude Medical, Plano, TX, USA).
The implanted SCS device, Prodigy™ (St. Jude Medical,
Plano, TX, USA), a constant current generator, is capable
of delivering both tonic and burst waveforms. Surgical
implant of the permanent system occurs approximately
4 to 8 weeks after the end of the trial evaluation period,
pursuant to usual care and surgical scheduling. After the
permanent implant, a surgical recovery period of 2 to
3 weeks occurs to allow for wound healing during which
transient medication increases were allowed.
Tonic stimulation pulse width is programmed in the usual
range of 100–500 μs, and tonic stimulation frequencies are
set at between 30 Hz and 100 Hz. Amplitudes for tonic
stimulation are programmed according to individual partici-
pant perception to a level that typically produces comfort-
able paresthesia. Burst programming for this study (see
Fig. 3) followed specific parameters such that 500-Hz stimu-
lation is delivered in groups of five pulses with 1-ms pulse
width, with bursts repeated 40 times per second. Charge
balance occurs during the 5 ms after each burst with passive
repolarization. Amplitudes for burst stimulation are pro-
grammed according to individual participant perception.
During the control phase of the study, participants are
advised that they might or might not experience paresthesia
at the outset of both waveforms.
Assessment tools
See Fig. 2 and Table 2 for a schedule of assessments.
Pain history and participant demographics
Upon enrollment, participants answer relevant questions
pertaining to pain history, previous treatment history, and
participant demographic information (including height,
weight, age, race, and marital status).
Pain
A daily Pain Diary is completed for the 7-day period
prior to each study visit. In the diary, participants are
asked to rate pain intensity using the Visual Analog
Scale (VAS), which consists of a horizontal line 100 mm
Table 1 Inclusion/exclusion criteria
Inclusion criteria
• Ability to provide informed consent
• Aged 22 years or older
• Chronic intractable neuropathic pain of the trunk and/or limbs
• Baseline average daily overall pain score of ≥60 on the Visual Analog
Scale collected with the 7-day Pain Diary
• Failed ≥3 documented medically supervised treatments (including, but
not limited to, physical therapy, acupuncture, etc.) as well as
treatment with ≥2 classes of medication
• Stable pain-related medication regimen 4 weeks prior to the screening
evaluation
• Deemed a good candidate for SCS by the investigator
• Deemed a suitable study candidate by a psychologist or psychiatrist
• Agrees not to add to or increase pain medication during the study
• Willing to cooperate with the study requirements, including
compliance with the regimen and completion of all office visits
• Female candidates of child-bearing potential agree to commit to the use
of an effective method of contraception for the duration of the study
Exclusion criteria
• Current participation in a clinical trial with an active treatment arm
• History of a neurostimulation trial or implanted system
• Presence of an infusion pump or any implantable neurostimulator
• Overall Beck Depression Inventory II score is >24 or, at the screening
visit, a score of 3 on Question 9 relating to suicidal thoughts or wishes
• Receiving, applying for, or considering workers’ compensation or
involved in disability litigation
• Concurrent clinically significant or disabling chronic pain problem that
requires additional treatment
• Existing medical condition that is likely to require repetitive MRI evaluation
• Existing medical condition that is likely to require the use of diathermy
• History of cancer requiring active treatment in the past 6 months
• Pain originating from peripheral vascular disease
• Participant is immunocompromised
• Documented history of allergic response to titanium or silicone
• Documented history of substance (narcotics, alcohol, etc.) abuse or
dependency in the 6 months prior to baseline
• Pregnancy (confirmed by positive urine/blood test)
MRI magnetic resonance imaging, SCS spinal cord stimulation
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in length, anchored by word descriptors on each end (no
pain to worst imaginable pain). Higher scores indicate
higher pain levels. Each diary entry includes four differ-
ent VAS scores to permit calculation of a weekly average
for daily overall pain, worst overall pain, trunk pain, and
limb pain. Participants arriving at the baseline visit with
less than seven diary entries repeat the baseline diary. If
repeating the baseline diary results in less than seven
entries, the participant is deemed a screening failure.
Participants complete the baseline pain diaries without
making changes to their current, stable pain medica-
tions. After randomization, missing diary entries are
accommodated during data analysis (see “Statistical
methods” section for more details).
Participants also complete the Short-Form McGill
Pain Questionnaire version 2 (SF-MPQ-2), a validated
questionnaire that measures the qualities of pain [13].
The SF-MPQ-2 is a self-administered questionnaire
consisting of 22 different pain descriptors. The par-
ticipant indicates the intensity of each pain descriptor
as it pertains to the participant’s pain experience.
Intensity ratings for each descriptor are provided on a
scale ranging from 0 (“none”) to 10 (“worst possible”).
The total SF-MPQ-2 score is the sum of the score of
three sensory subscales (continuous, intermittent, and
predominantly neuropathic pain descriptors) and one
affective subscale. Higher scores indicate a higher
severity of symptoms.
Medication
Throughout the study, site study personnel complete a
medication log to track the participants’ reported daily
doses and names of pain medications (prescription and
over-the-counter) and medications known to affect pain
perception (e.g., certain antidepressants).
Quality of life
The SF-36v2™ Health Survey [14] is a validated, self-
administered short-form health questionnaire with 36
questions. Scoring produces eight subscale scores for
vitality, physical functioning, bodily pain, general health
perceptions, physical role functioning, emotional role
functioning, social role functioning, and mental health.
These eight subscales are used to calculate two summary
component scores for physical and mental health.
Higher scores indicate a better quality of life.
Pain catastrophizing
The Pain Catastrophizing Scale (PCS) is a validated scale
to assess the quality of thoughts and feelings during pain
[15]. The PCS includes 13 statements for which partici-
pants rate the frequency with which the statement
matches their pain experience, from 0 (“not at all”) to 4
(“always”). The scale is self-administered, takes 5 min to
complete, and examines three domains: rumination,
magnification, and helplessness. A higher score indicates
a higher level of catastrophizing.
Disability
The Oswestry Disability Index 2.1a (ODI) is a validated
low-back pain questionnaire that indicates the extent to
which a person’s functional level is restricted by disability
[16]. The self-administered questionnaire includes 10
questions and takes approximately 5 min to complete.
The questionnaire produces a percentage total score that
Fig. 3 Waveforms. Tonic stimulation provides a consistent stream of pulses at a set frequency, pulse width, and amplitude. Burst stimulation
delivers groups of pulses at a lower amplitude and a higher frequency than tonic stimulation. Bursts of pulses are followed by pulse-free periods
during which charge balance occurs
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indicates the degree of disability; a higher percentage indi-
cates a greater disability.
Mood
The Beck Depression Inventory BDI-II is a 21-question
validated assessment that evaluates the intensity of
depressive symptoms [17]. The questionnaire takes
approximately 5 min to complete. The total score is
categorized by minimal, mild, moderate, and severe
depression. Higher total scores indicate more severe
depressive symptoms.
Pain and paresthesia mapping
Pain location is documented on a map of the body labeled
with different numbered segments. The participant is
instructed to shade-in or place an “X” in the area(s) of pain.
Paresthesia mapping is documented using a body map
similar to that used for pain location mapping. The par-
ticipant is instructed to shade-in or place an “X” in the
area(s) for which they experience paresthesia or other
perceptible stimulation sensations. Participants are also
asked to indicate the area or areas on the body map for
which pain relief translates to the greatest improvement
for their daily activities.
Patient Global Impression of Change
At the 12-and 24-week visits and at all long-term
follow-up visits, participants are asked to complete a
standard seven-item Patient Global Impression of
Change (PGIC) Likert scale, ranging from “no change”
to “a great deal better.”
Therapy preference and satisfaction
After using both therapy types (at 24 weeks), partici-
pants are asked to indicate which waveform they prefer
and to provide a reason for their preference.
At each follow-up, participants are asked to rate satis-
faction with the device by selecting from the following
options on a 5-point Likert scale: very satisfied, satis-
fied, neither satisfied nor dissatisfied, dissatisfied, or
very dissatisfied.
Adverse events
Adverse events (AEs) are recorded for enrolled partici-
pants at any visit, including unscheduled visits. AEs are
classified according to their relationship to the device(s)
and/or procedures and according to severity. All AEs,
regardless of the reason or severity, are followed with
appropriate corrective actions by the investigators until
a satisfactory resolution is obtained.
Study visits
Table 2 shows the assessments scheduled for each study
visit. At the enrollment visit, participants adhering to the
initial inclusion/exclusion criteria sign informed consent,
complete assessments, and start the VAS Pain Diary. If
required of female participants, a pregnancy test is per-
formed. Participants who meet all the inclusion/exclusion
criteria after initial assessments and completion of the base-
line Pain Diary complete additional assessments and are
scheduled for the tonic stimulation trial evaluation period
for 3–7 days. Participants with a successful trial, defined as
a patient-reported pain reduction of at least 50%, proceed
to a permanent implant. After a surgical recovery period of
2–3 weeks, participants are randomized (1:1 at each site)
using an online electronic program provided by St. Jude
Table 2 Study visits and associated assessments
Visit Assessments
Enrollment and screening • Pain history and demographics
• BDI-II
• Pain Location Form
• Medications
• Provide subject with the 7-day
Pain Diary for the baseline
evaluation






Trial system implantation • 7-day Pain Diary returned
• Medications
End of trial visit (4–8 days after
trial system implantation)
• Medications
• End-of-trial physician assessment
System implantation • Medications
• Physician’s record surgical
summary for the procedure,
including any complications
Randomization/activation • Medications
• Participant programming record
Control phase follow-up visits
(Occurring at 6, 12, 18, and 24
weeks after randomization)








End of control phase (Assessments
occurring at the 24-week visit, in
addition to those described above)
• PGIC
• Patient preference
Open-label phase follow-up visits
(Occurring every 6 months for up
to 2 years)








BDI-II Beck Depression Inventory BDI-II, OD12.1a Oswestry Disability Index 2.1a,
PCS Pain Catastrophizing Scale, PGIC Patient Global Impression of Change, SF-
36v2TM Short-form 36 Health Survey, SF-MPQ-2 Short-Form McGill Pain
Questionnaire version 2
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Medical and the prescribed programming is activated. All
participants receive a patient programmer that enables acti-
vation of the ON and OFF positions and adjustments to
amplitude within the prescribed range.
During the control phase of the study, participants at-
tend follow-up visits at the mid-point and end of each of
the two 12-week phases of treatment. At the 12-week
visit, participants cross over to the second stimulation
mode of their treatment sequence and continue in the
study for an additional 12 weeks (through 24 weeks).
Participants are programmed to their preferred stimu-
lation mode at the end of the 24-week visit. Subse-
quently, participants attend follow-up visits every
6 months for up to 2 years. During this open-label
phase, participants can request reprogramming and
may use either stimulation mode or both, as needed to
maintain adequate therapeutic benefit.
Statistical methods and data management
Data management, including monitoring, is performed by
the study sponsor to ensure data completeness and accur-
acy. Additionally, a noninvestigator physician Steering
Committee performs data review and adjudication. As
part of standard practice for IDE studies, the FDA
conducts occasional audits of the study conduct, data col-
lection, and data management. Study investigators will
have access to the data after study closure and will be
offered the opportunity to participate as authors on publi-
cations. Electronic data capture with appropriate security
protocols is used to ensure participant confidentiality
during and after the study closure.
Statistical analyses will be performed using a signifi-
cance level of p = 0.05, unless otherwise specified, and
95% confidence intervals will be computed. Interim
analyses for the primary endpoint will occur when all
randomized participants complete the 24-week visit; re-
sults of that analysis will be submitted for publication.
Analyses of the long-term follow-ups will be reported
after study closure.
Sample size
Noninferiority of the VAS score during burst compared
with tonic stimulation was assumed to be within a window
of 7.5 mm on the 100-mm VAS. Based on earlier reports,
the standard deviation of the difference between tonic and
burst stimulation VAS scores was assumed to be 18.4 mm.
With a type I error rate of 0.05, a minimum sample of 76
participants was required to achieve 80% power to show
noninferiority between the two stimulation modes.
Previous studies indicate that approximately 29% of sub-
jects trialed with tonic stimulation do not receive a per-
manent implant and an additional 20% of subjects may be
lost to attrition by the 6-month visit [18]. Screen failure
rates were originally estimated to be at 15%, but after the
first 6 months of enrollment the screen failure rate was
amended to 22%. Total enrollment communicated with
the regulatory bodies was 173 to account for screen
failures, trial evaluation failures, and normal attrition [76/
.71 = 108/.80 = 135/.78 = 173 (rounding up at each step)].
The noninferiority margin was set to preserve at least
50% of the expected effect [19, 20]. Assuming, based upon
enrollment criteria and past literature [21], the average
baseline pain is approximately 75 mm, a 30% improve-
ment in VAS score would be 23 mm. The 7.5-mm margin
on the VAS scale would preserve approximately 77% of
the effect and would, therefore, be an appropriate margin.
Carryover estimations
Prior to analysis, measures will be inspected for carryover
effects that may be present as a function of time and/or
the order of therapy delivery. Carryover effects will be esti-
mated using the within-subject sums of the score from
week 1 to week 12 and from week 12 to week 24. An inde-
pendent two-sided t test will test the null hypothesis of
equal within-subject sums between the two sequence
groups tonic/burst stimulation and burst/tonic stimula-
tion. If the null hypothesis is not rejected at the 0.10 level,
then the potential carryover effects are considered negli-
gible. If the null hypothesis is rejected, the subsequent
analysis will be carried out on the first-period data only.
Primary analysis
The primary effectiveness analysis is the 12-week nonin-
feriority of the within-subject difference between tonic
and burst stimulation for the mean daily overall VAS
score calculated from the diary. The primary analysis
will be conducted using the intention-to-treat popula-
tion to include data recorded at the 12- and 24-week
visits for all randomized participants, except as noted
below. Missing data will be imputed using the hot-deck
or last-observation-carried-forward method, as appropri-
ate. If participants increase their pain medications dur-
ing the first 24 weeks of the study, assessment of the
effect of the therapy mode on pain will be confounded
by the influence of additional pain medications. Thus,
participants who increase pain medication (other than
acetaminophen) after randomization will be considered
treatment failures for the interval during which the in-
crease occurred, and that participant’s baseline mean
daily VAS score will be used for that interval in the ana-
lysis. A Z-statistic compared with the standard normal
distribution will test the null hypothesis that the within-
subject difference for the mean overall VAS score is less
than or equal to 7.5 mm.
Additional analyses
For the control phase of the study, a responder analysis
will inspect the proportion of participants achieving a
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change from baseline of 30% or greater for the overall
VAS score during each stimulation mode. If noninferiority
of burst stimulation is established in the primary endpoint
analysis, the superiority of burst versus tonic stimulation
will be tested for the overall VAS score using a one-sided t
test. The within-subject difference for trunk and limb VAS
scores will be inspected using two-sided 95% confidence
intervals. The presence of paresthesiae will be compared
between the two stimulation modes, and a relative differ-
ence of the within-subject experience will be computed.
All other measures will be inspected using appropriate
descriptive statistics and within-subject comparisons of
burst versus tonic stimulation. Additional analyses will
also include inspection of results in an intention-to-treat
population to include all randomized participants; conser-
vative imputations for missing data or participant with-
drawal will be made in a manner appropriate to the
measure and pattern of missing data.
During the open-label phase, type of therapy was
chosen by the participant. Appropriate longitudinal
statistics will examine long-term outcomes with the
device- and participant-selected stimulation modes. Com-
parative analyses for burst versus tonic stimulation for this
phase will be performed if statistically appropriate.
Safety
The safety profile of both stimulation modes will be
characterized using appropriate descriptive statistics
(e.g., incidence rates).
Discussion
As the first large randomized controlled study of burst
stimulation, the design is intended to provide evidence to
support FDA approval of the burst neuromodulation wave-
form for the treatment of chronic neuropathic pain by es-
tablishing noninferiority of burst stimulation to traditional
tonic stimulation. The results of this study will provide
comparative efficacy and safety for burst stimulation in pa-
tients who are candidates for traditional SCS. Additionally,
data from this study will provide evidence for the psycho-
social and functional outcomes during both stimulation
modes. The two phases of this study will facilitate compari-
sons between the waveforms as well as inspection of prefer-
ence and long-term usage patterns for up to 2 years when
the leads are placed for tonic stimulation. Chronic pain and
responses to neurostimulation are both complex sensory
phenomena. The ability to have patients experience the
control and experimental stimulation modes is a unique
feature of this study design, which should facilitate mean-
ingful patient preference assessment.
The enrichment strategies for this study design confer
advantages for our primary aim. The within-subject
comparisons help to control variability in the data such
that lead location, programming, and other participant-
specific variables are held constant. Additionally, only
participants who respond to tonic stimulation during the
trial evaluation period and are candidates for a traditional
SCS system are randomized, which should minimize par-
ticipant attrition while facilitating comparative efficacy in
patients who are known candidates for SCS. Ideal elec-
trode placement for burst stimulation may not be at the
site chosen for tonic stimulation, as in the present study.
The same might be true of other waveforms; further study
is required to address these points.
Furthermore, participants with marked depressive symp-
toms are excluded from eligibility in this study. Affective
and functional dimensions are reflected in patients’ impres-
sion of change – even when a reduction in pain intensity
may be considered clinically minimal [22]. Affective disrup-
tions commonly associated with pain may also interfere
with an accurate assessment of changes in pain intensity.
Our study is intended to provide a comparative inspection
of pain during burst and tonic stimulation that is largely
independent of affective improvements that may indirectly
influence participant’s assessment of therapy. We recognize
that a minority of chronic pain patients, as few as 14% by
some accounts, present without significant depressive
symptoms [23, 24]. Excluding participants with depressive
symptoms is not expected to limit generalizability, however,
because the population included in this design is expected
to provide a conservative estimate of pain relief during
stimulation. Any direct or indirect benefits to affective
function conferred by burst stimulation would be expected
to be additive, not exclusive, to the effects on pain. Thus,
the results of this study would be expected to approximate,
possibly to a lesser degree, the efficacy of burst stimulation
for general clinic populations.
In contrast, our sample of participants with minimal
affective disruption is likely to create a “floor effect”
whereby comparative improvements in psychosocial out-
comes for burst versus tonic stimulation are unlikely to be
detectable. Early evidence indicates that some psycho-
social domains may be differentially affected during burst
stimulation compared to tonic stimulation [5]; future
studies will be needed to target this aspect of the therapy.
The cross-over design also imposes some limitations
upon the hypotheses that can be addressed with these re-
sults. First, the presence of any carryover effects, although
not expected, may limit our analysis by reducing the treat-
ment window to the first 3-month period – thus leading
to a between-subject comparison. Second, we will be un-
able to statistically assess changes in pain across time
without losing the benefits of the within-subject design.
Much of the literature for chronic pain treatments focuses
on a calculated change in pain from baseline to follow-up.
Our study design is not intended for such an analysis and
any inspection of the similar results in our study will lead
to limited conclusions, at best.
Slavin et al. Trials  (2016) 17:569 Page 9 of 11
As with all studies, the design described herein is not
without its limitations; however, this study represents the
first large randomized controlled trial comparing the burst
waveform with previously approved tonic waveforms. Ul-
timately, we expect to collect and report data leading to
FDA approval for the device that can offer both burst and
tonic waveforms, leading to individualized therapy strat-
egies through enhanced therapeutic options.
Trial status
The study is ongoing.
Additional file
Additional file 1: SPIRIT Checklist. (PDF 130 kb)
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